George Castro, MD
Pulmonary Disease · New York, NYNPI 1992852941
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 362 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by GSK at 26.8% of the total. 2025 is the largest year on record at $3,309, more than ten times the $95 reported in 2019.
Across 362 payments — averaging $23.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$1K
- Gilead$953
- Sanofi$673
- Regeneron Healthcare Solutions, Inc.$510
- Viiv Healthcare Company$486
- plus $2K from 20 others
What the payments were for
- Food & beverage$8,32299%
- Education$841%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 116 | $2,249 |
| AstraZeneca | 64 | $1,477 |
| Gilead | 43 | $953 |
| Sanofi | 22 | $673 |
| Regeneron Healthcare Solutions, Inc. | 17 | $510 |
| Viiv Healthcare Company | 17 | $486 |
| Mallinckrodt Hospital Products Inc. | 13 | $360 |
| Novo Nordisk | 12 | $278 |
| Amgen | 9 | $236 |
| Phathom Pharmaceuticals, Inc. | 10 | $220 |
| Boehringer Ingelheim | 8 | $183 |
| Lilly USA, LLC | 6 | $163 |
| Verona Pharma, Inc. | 5 | $132 |
| Baxter Healthcare | 3 | $77 |
| Viatris Specialty LLC | 2 | $59 |
| Corcept Therapeutics | 2 | $56 |
| Pfizer | 2 | $53 |
| Paratek Pharmaceuticals, Inc. | 2 | $41 |
| Inspire Medical Systems, Inc. | 1 | $37 |
| Hikma Pharmaceuticals USA | 2 | $35 |
| Vifor Pharma, Inc. | 1 | $27 |
| AbbVie | 1 | $25 |
| Phadia US Inc. | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Zimmer Biomet | 1 | $19 |
| Electromed, Inc. | 1 | $17 |
How this compares
$8,406 in reported general payments places this provider in the 80th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $92,132 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 18 | $74,343 |
| OzempicSemaglutide | 53 | $58,836 |
| Dupixent PenDupilumab | 12 | $41,566 |
| EliquisApixaban | 34 | $39,618 |
| MounjaroTirzepatide | 19 | $18,886 |
| JanuviaSitagliptin Phosphate | 11 | $18,488 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $15,451 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $14,070 |
| ZenpepLipase/Protease/Amylase | 22 | $13,390 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $5,729 |
| Lamivudine-ZidovudineLamivudine/Zidovudine | 22 | $5,475 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $2,103 |
| Omeprazole | 135 | $1,414 |
| Atorvastatin Calcium | 174 | $1,172 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $2,249 | $113,313156 claims |
| GileadBiktarvy | $953 | $74,34318 claims |
| Novo NordiskOzempic | $278 | $58,83653 claims |
| PfizerEliquis | $53 | $39,61834 claims |
| Lilly USA, LLCMounjaro | $163 | $18,88619 claims |
| AstraZenecaBreztri Aerosphere | $1,477 | $14,07016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Josanna Rodriguez-LopezNew York$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.